Investigative Ophthalmology & Visual Science Cover Image for Volume 58, Issue 8
June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Relationship Between Optical Coherence Tomography Angiography Macular Vascular Density Measurements and Central Visual Field Damage
Rafaella Cleto Penteado; Linda M Zangwill; Fabio Bernardi Daga; Mark Christopher; Adeleh Yarmohammadi; Patricia Isabel C Manalastas; Tadamichi Akagi; Takuhei Shoji; Felipe Medeiros; Robert N Weinreb
Author Affiliations & Notes
  • Rafaella Cleto Penteado
    Hamilton Glaucoma Center, Shiley Eye Institute, Department of Ophthalmology, University of California, San Diego, San Diego, California, United States
  • Linda M Zangwill
    Hamilton Glaucoma Center, Shiley Eye Institute, Department of Ophthalmology, University of California, San Diego, San Diego, California, United States
  • Fabio Bernardi Daga
    Hamilton Glaucoma Center, Shiley Eye Institute, Department of Ophthalmology, University of California, San Diego, San Diego, California, United States
  • Mark Christopher
    Hamilton Glaucoma Center, Shiley Eye Institute, Department of Ophthalmology, University of California, San Diego, San Diego, California, United States
  • Adeleh Yarmohammadi
    Hamilton Glaucoma Center, Shiley Eye Institute, Department of Ophthalmology, University of California, San Diego, San Diego, California, United States
  • Patricia Isabel C Manalastas
    Hamilton Glaucoma Center, Shiley Eye Institute, Department of Ophthalmology, University of California, San Diego, San Diego, California, United States
  • Tadamichi Akagi
    Hamilton Glaucoma Center, Shiley Eye Institute, Department of Ophthalmology, University of California, San Diego, San Diego, California, United States
    Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
  • Takuhei Shoji
    Hamilton Glaucoma Center, Shiley Eye Institute, Department of Ophthalmology, University of California, San Diego, San Diego, California, United States
    Department of Ophthalmology, Saitama Medical University, Iruma, Japan
  • Felipe Medeiros
    Hamilton Glaucoma Center, Shiley Eye Institute, Department of Ophthalmology, University of California, San Diego, San Diego, California, United States
  • Robert N Weinreb
    Hamilton Glaucoma Center, Shiley Eye Institute, Department of Ophthalmology, University of California, San Diego, San Diego, California, United States
  • Footnotes
    Commercial Relationships   Rafaella Penteado, None; Linda Zangwill, Carl Zeiss Meditec Inc. (F), Heidelberg Engineering GmbH (F), National Eye Institute (F), Optovue Inc. (F), Topcon Medical Systems Inc. (F); Fabio Daga, None; Mark Christopher, None; Adeleh Yarmohammadi, None; Patricia Isabel Manalastas, None; Tadamichi Akagi, Alcon (R), Kowa (R), Pfizer (R), Santen (R), Senju (R); Takuhei Shoji, Alcon (R), Kowa (R), Otsuka (R), Pfizer (R), Santen (R), Senju (R); Felipe Medeiros, Alcon (F), Alcon (R), Allergan (C), Allergan (F), Allergan (R), Bausch & Lomb (F), Carl Zeiss Meditec (C), Carl Zeiss Meditec (F), Carl Zeiss Meditec (R), Heidelberg Engineering (F), Merck (F), National Eye institute (R), Novartis (C), Reichert (F), Reichert (R), Sensimed (F), Topcon (F); Robert Weinreb, Aerie Pharmaceutical (C), Alcon (C), Allergan (C), Bausch & Lomb (C), Carl Zeiss Meditec (F), Eyenovia (C), Forsight Vision V (C), Genentech (F), Heidelberg Engineering (F), Optovue (F), Quark (F), Sensimed (C), Topcon (F), Unity (C)
  • Footnotes
    Support  UCSD Vision research core grant EY0222589; NIH Grants P30EY022589, EY11008, EY019869, EY021818, and participant retention incentive grants in the form of glaucoma medication at no cost from Alcon Laboratories Inc, Allergan, Pfizer Inc, and Santen Inc. Unrestricted grant from Research to Prevent Blindness, New York, New York.
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 4262. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Relationship Between Optical Coherence Tomography Angiography Macular Vascular Density Measurements and Central Visual Field Damage
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Rafaella Cleto Penteado, Linda M Zangwill, Fabio Bernardi Daga, Mark Christopher, Adeleh Yarmohammadi, Patricia Isabel C Manalastas, Tadamichi Akagi, Takuhei Shoji, Felipe Medeiros, Robert N Weinreb; Relationship Between Optical Coherence Tomography Angiography Macular Vascular Density Measurements and Central Visual Field Damage. Invest. Ophthalmol. Vis. Sci. 2017;58(8):4262.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose : To evaluate the association between macular vascular density assessed by optical coherence tomography angiography (OCT-A) and central visual field results in normal, glaucoma suspects and glaucoma eyes.

Methods : Participants of the Diagnostic Innovations in Glaucoma Study (DIGS) who had OCT-A images of the macula (AngioVue; Optovue, Freemont, CA) and central visual field 10-2 test were selected for this cross-sectional study. Only macular (3.0 x 3.0 mm) OCT-A scans labelled as having good quality according to the University of California, San Diego Imaging Data Evaluation and Analysis (IDEA) Reading Center protocol were included. The associations between central visual field mean deviation (MD), and both superficial macular whole-image vessel density (wiVD) and perifoveal vessel density (pfVD) were assessed using linear regression. Analysis of Variance (ANOVA) was performed to evaluate the differences in wiVD and pfVD amongst the different diagnostic groups.

Results : A total of 235 eyes from 41 healthy participants, 44 glaucoma suspects, 94 mild glaucoma patients, and 56 moderate to severe glaucoma patients were included. Mean wiVD (52.52%, 49.52%, 49.17% and 45.30%, respectively) and mean pfVD (54.84%, 51.83%, 51.87% and 47.74%, respectively) were found to be significantly higher in healthy eyes compared to glaucoma suspects and glaucoma patients with mild and severe disease in these four diagnostic groups (ANOVA p<0.001, and post-hoc Tukey-Kramer Test). The association between SAP 10-2 MD and wiVD (R2=15.87%) and between SAP 10-2 MD and pfVD (R2=14.74%) were statistically significant (p<0.001 for both).

Conclusions : Macular vascular density assessed by OCT-A is lower in patients with moderate to severe glaucoma when compared to healthy eyes, glaucoma suspects or mild glaucoma. Whole-image vessel density and perifoveal vessel density are also correlated with central visual field (SAP 10-2) mean deviation results, and future studies with macular OCT-A should be done in order to evaluate disease progression.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

 

Figure 1. Boxplot depicting the distribution of macular whole-image vessel density (wiVD, in blue) and perifoveal vessel density (pfVD, in red) for healthy eyes, glaucoma suspects, mild glaucoma patients, and moderate to severe glaucoma patients.
View OriginalDownload Slide

Figure 1. Boxplot depicting the distribution of macular whole-image vessel density (wiVD, in blue) and perifoveal vessel density (pfVD, in red) for healthy eyes, glaucoma suspects, mild glaucoma patients, and moderate to severe glaucoma patients.

Figure 1. Boxplot depicting the distribution of macular whole-image vessel density (wiVD, in blue) and perifoveal vessel density (pfVD, in red) for healthy eyes, glaucoma suspects, mild glaucoma patients, and moderate to severe glaucoma patients.

Figure 1. Boxplot depicting the distribution of macular whole-image vessel density (wiVD, in blue) and perifoveal vessel density (pfVD, in red) for healthy eyes, glaucoma suspects, mild glaucoma patients, and moderate to severe glaucoma patients.
View OriginalDownload Slide

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Attribution-NonCommercial-NoDerivatives
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept